Reformulary Group launches COVID-19 DEW Report
Twice-weekly summary of emerging pharmaceutical developments to be posted at Reformulary.com
TORONTO, March 31, 2020 - Reformulary Group, a Canadian healthcare technology company, today announced the launch of its COVID-19 DEW (Drug Early Warning) Report, powered by Reformulary®.
A publicly available resource, the COVID-19 DEW Report will be updated twice each week on Reformulary.com to aggregate and summarize the highest quality, most relevant news sources on emerging developments related to the rush to find a treatment and eventual vaccine for COVID-19.
Reformulary Group has built a reputation as a team of experts helping Canadians make sense of medicine, something that is never more important than at a time of crisis and rapidly changing information. Reformulary’s Drug Early Warning (DEW) System™ monitors drugs between 12 and 18 months prior to receiving regulatory approvals; based on algorithms, DEW can predict the impact of these drugs on drug plans. The company has reviewed 93 drugs in the pipeline over the past four years.
“Canadians find themselves bombarded with information about potential COVID-19 vaccines, cures, supposed home fixes and unfortunately sometimes dangerous, unapproved use of certain drugs. We are leveraging our expertise to cut through the noise and bring insurance industry players and concerned citizens alike current, accurate and relevant news on pharmaceutical developments related to COVID-19,” said Helen Stevenson, Founder and CEO of Reformulary Group.
Content will be updated on Tuesdays and Fridays each week and will be vetted by a member of Reformulary Group’s expert medical committee. The updates will be live at https://reformulary.com/covid19.
About Reformulary Group
Founded in 2011, Reformulary Group is an expert-led healthcare company focused on helping Canadians make sense of medicine. The company’s proprietary drug list, the Reformulary®, and award-winning DrugFinder™ digital tool provide Canadians with valuable comparative drug information, reviewed and vetted by an independent committee of doctors and pharmacists from across Canada. Reformulary Group built Cannabis Standard™, a discovery tool to guide medical cannabis use. Cannabis Standard also enables patients to track the impact of medical cannabis on their quality of life using a survey tool recognized by healthcare professionals worldwide. For more information visit www.reformulary.com.